A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
about
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisHigh-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancerCOX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis.Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature reviewDivergent evolution of an atypical S-adenosyl-l-methionine-dependent monooxygenase involved in anthracycline biosynthesis.HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safetyThe role of peptide and DNA vaccines in myeloid leukemia immunotherapyHAG regimen improves survival in adult patients with hypocellular acute myeloid leukemiaGranulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell lineDose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study.Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
P2860
Q33404677-F971FF8E-AEF9-47E3-AC60-F14009543053Q34752832-50B09747-5EA7-41E9-B86E-E68FF33789C0Q34984281-DA5F47B4-7B88-4BEE-9140-436AA8D76137Q35742255-543544B7-5FF2-4B2F-8782-B91139BED7D6Q35961223-57F57DA0-2C5D-4338-9E0A-7D7912534BF5Q36153981-5753ECCA-D88F-4ABE-8830-4AB6F687BB74Q36444510-EF9BBB18-4725-4246-9E20-9E7059F2D9C5Q36608571-A92A89F1-5172-4677-B9C2-CF81B79FFAF0Q36772225-F0083543-9F9A-465F-AC32-CF963A449959Q37001216-10D375DC-67AA-477C-9EA5-DFA16B457FE6Q37036452-AF7A9746-D989-413D-BD27-BC55F6EF1186Q40256523-1814BD50-AFB9-46E7-A3D1-8E641319580BQ51594039-D1C50AAD-3A75-4350-A826-B578DA26BA72Q52770446-ABE8A731-629A-4626-8D2C-7A90BA395534Q53583157-1A039F28-58B5-4241-8A70-C38C13DC6085
P2860
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@ast
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@en
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@nl
type
label
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@ast
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@en
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@nl
prefLabel
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@ast
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@en
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@nl
P2093
P2860
P31
P921
P3181
P356
P1476
A meta-analysis of CAG (cytara ...... a and myelodysplastic syndrome
@en
P2093
Delong Liu
Guoqing Wei
Jen-wei Chiao
P2860
P2888
P3181
P356
10.1186/1756-8722-4-46
P407
P5008
P577
2011-11-14T00:00:00Z
P5875
P6179
1052005654